Trevi Therapeutics to participate in upcoming September conferences
Trevi Therapeutics says it will participate in upcoming September conferences, highlighting its investigational therapy Haduvio for chronic cough in patients with idiopathic pulmonary fibrosis and non-IPF.
NEW HAVEN, Conn., Sept.
03, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc.
NASDAQ:TRVI, a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF…